The pharmacokinetics of etanercept in healthy volunteers

被引:1
|
作者
Korth-Bradley, JM
Rubin, AS
Hanna, RK
Simcoe, DK
Lebsack, ME
机构
[1] Wyeth Ayerst Res, Clin Pharmacokinet, Philadelphia, PA 19101 USA
[2] Immunex Corp, Biometr, Seattle, WA 98101 USA
[3] Immunex Corp, Analyt Resources Dept, Seattle, WA 98101 USA
关键词
phamacokinetics; etanercept;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: TO describe the pharmacokinetics of etanercept when administered by subcutaneous injection in single doses to healthy volunteers, METHODS: Twenty-six healthy volunteers between 19 and 50 years of age received single doses of etanercept 25 mg by subcutaneous injection into the abdomen. Serial serum samples were collected for 21 days. An enzyme-linked immunosorbent assay with a quantitation limit of 0.3 ng/mL was used to measure the drug concentrations. RESULTS: Etanercept was well tolerated by healthy volunteers. A one-compartment model was found to best describe the concentration-time data and was used to determine the pharmacokinetic parameters. Etanercept is slowly absorbed from the site of injection with a time of peak concentration (+/- SD) of 51 +/- 14 hours; peak concentration was 1.46 +/- 0.72 mg/L. The AUC was 235 +/- 98 mg.h/L, apparent clearance was 132 +/- 85 mL/h, apparent volume of distribution was 12 +/- 6 L, and the half-life was 68 +/- 19 hours. CONCLUSIONS: Etanercept was slowly absorbed and slowly eliminated after subcutaneous administration. Dosing at the recommended rate of 25 mg twice weekly would be expected to result in concentrations of approximately 3 mg/L. Intersubject variability for apparent clearance in healthy volunteers was 64%.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 50 条
  • [41] Psoriatic arthritis and etanercept
    Pedraz, J.
    Dauden, E.
    ACTAS DERMO-SIFILIOGRAFICAS, 2010, 101 : 26 - 34
  • [42] Etanercept, anticytokines and mania
    Kaufman, KR
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2005, 20 (04) : 239 - 241
  • [43] Etanercept in antiphospholipid syndrome
    Joan T. Merrill
    Current Rheumatology Reports, 2003, 5 (5) : 381 - 381
  • [44] QL0902, a proposed etanercept biosimilar: pharmacokinetic and immunogenicity profile to its reference product in healthy Chinese male subjects
    Zeng, Yun
    Huang, Jie
    Cui, Chang
    Yang, Shuang
    Zhang, Ze-Yu
    Ali, Saqib
    Huang, Zhi-Jun
    Yang, Guo-Ping
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 105 - 110
  • [45] Erfolgreiche Therapie mit Etanercept bei rezidivierender PolychondritisSuccessful therapy with etanercept in relapsing polychondritis
    C. Schräder
    J. Lohmann
    Zeitschrift für Rheumatologie, 2010, 69 (4) : 356 - 358
  • [47] Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory Study
    van Bezooijen, Ji Sun
    Balak, Deepak M. W.
    van Doorn, Martijn B. A.
    Looman, Caspar W. N.
    Schreurs, Marco W. J.
    Koch, Birgit C. P.
    van Gelder, Teun
    Prens, Errol P.
    DERMATOLOGY, 2016, 232 (04) : 407 - 414
  • [48] Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis
    Bader-Meunier, Brigitte
    Krzysiek, Roman
    Lemelle, Irene
    Pajot, Christine
    Carbasse, Aurelia
    Poignant, Sylvaine
    Melki, Isabelle
    Quartier, Pierre
    Choupeaux, Laure
    Henry, Elodie
    Treluyer, Jean-Marc
    Belot, Alexandre
    Hacein-Bey-Abina, Salima
    Urien, Saik
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 48 (06) : 1014 - 1018
  • [49] Etanercept and infection - latent tuberculosis
    Gonzalez-Sixto, B.
    Rodriguez-Prieto, M. A.
    ACTAS DERMO-SIFILIOGRAFICAS, 2010, 101 : 62 - 68
  • [50] Temporary interruption of treatment with etanercept
    Ruiz-Genao, D. P.
    Lopez-Estebaranz, J. L.
    ACTAS DERMO-SIFILIOGRAFICAS, 2010, 101 : 102 - 105